Is This the Right Time to Add CRL Stock to Your Portfolio?
Charles River's improving DSA demand and strategic investments support growth, but uneven recovery and NHP cost volatility remain key risks.
Yahoo3 days agoCRL
Charles River Laboratories International (CRL) Price Target Increased by 17.31% to 274.25
Fintel7 days agoCRL
Animal Testing and Non-Animal Alternative Testing Market Outlook 2025-2035 - Featuring Profiles of Charles River Laboratories, Labcorp, and Eurofins Scientific
Opportunities center on non-animal, pharma and regulatory testing, driven by organ-on-chip, organoids, AI biosimulation, genomics and in vitro toxicity platforms.Dublin, Aug. 27, 2026 (GLOBE NEWSWIRE) -- The "Animal Testing and Non-Animal Alternative Testing Global Market Opportunities and Strategies to 2035" has been added to ResearchAndMarkets.com's offering. The latest animal testing and non-animal alternative testing market report provides a comprehensive analysis of industry performance fro
Yahoo8 days agoCRL
Is Wall Street Bullish or Bearish on Charles River Laboratories Stock?
Charles River Laboratories has significantly outperformed the market, while strong guidance and a bullish analyst outlook support continued optimism.
Yahoo9 days agoCRL
Here's How Much $100 Invested In Charles River 15 Years Ago Would Be Worth Today
Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 2.75% on an annualized basis producing an average annual return of 15.76%. Currently, Charles River has a market capitalization of $15.22
Benzinga10 days agoCRL
Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?
Here is how Cardiol Therapeutics Inc. (CRDL) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.
Yahoo10 days agoCRL
3 Inflated Stocks We Approach with Caution
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.
Yahoo10 days agoCRL
Does Charles River (CRL)–Medigen Vaccine Work Sharpen the Case for Its Complex Biologics Edge?
Earlier this week, Medigen Vaccine Biologics Corp. announced a collaboration with Charles River Laboratories International to characterize and validate the virus seed bank for its next-generation multivalent enterovirus vaccine, with Charles River providing advanced analytical support including Next-Generation Sequencing for key Chemistry, Manufacturing, and Controls activities. The partnership highlights Charles River’s role as a specialized partner for complex biologics testing and...
Yahoo13 days agoCRL
Why Is Charles River Laboratories International (CRL) Pushing Deeper Into Vaccine Development?
Charles River Laboratories International (NYSE:CRL) and Medigen Vaccine Biologics announced a collaboration to develop next-generation enterovirus vaccines using advanced analytics and next-generation sequencing. The partnership focuses on using detailed analytical methods to support faster vaccine development timelines and regulatory compliance. Both companies plan to apply novel testing approaches that aim to reduce reliance on animal studies in future vaccine programs. The agreement is...
Yahoo13 days agoCRL
Are Options Traders Betting on a Big Move in Charles River Stock?
Investors need to pay close attention to CRL stock based on the movements in the options market lately.
Yahoo14 days agoCRL
Charles River Gains 88.6% in a Year: What's Driving the Rally?
CRL's shares have surged 88.6% in a year as DSA returns to organic growth, bookings climb and new testing initiatives broaden its strategy.
Yahoo14 days agoCRL
Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing
WILMINGTON, Mass., August 20, 2026--Charles River Laboratories International, Inc. (NYSE: CRL) and Medigen Vaccine Biologics Corp. (MVC) collaborate on the characterization and validation of the virus seed bank for MVC's next-generation multivalent enterovirus vaccine. Charles River will leverage its advanced analytical platforms, including Next-Generation Sequencing (NGS), to support critical steps of Chemistry, Manufacturing, and Controls (CMC) activities for MVC’s next-generation multivalent
Yahoo15 days agoCRL
Charles River Laboratories And Medigen Vaccine Biologics Collaborate On Characterization And Validation Of Virus Seed Bank For MVC's Next-Gen Multivalent Enterovirus Vaccine
Collaboration leverages NGS technologies to accelerate high-quality vaccine development, support global regulatory readiness, and help reduce animal testingCharles River Laboratories International, Inc. (NYSE:CRL) and
Benzinga15 days agoCRL
Protein Design & Engineering Market Global Report 2026: Evaluating AI Platforms, Rational Design, Directed Evolution, and Strategies of Lonza, Thermo Fisher, GenScript, and Charles River
Opportunities span AI-driven protein design and structure prediction, precision therapeutics, engineered biologics and vaccines, synthetic biology, novel enzymes, high-throughput screening, and advanced computational modeling, with Asia-Pacific offering expansion potential. Protein Design and Engineering Market Protein Design and Engineering Market Dublin, Aug. 19, 2026 (GLOBE NEWSWIRE) -- The "Protein Design and Engineering Market Global Report 2026" has been added to ResearchAndMarkets.com's o
Yahoo16 days agoCRL
If You Invested $100 In Charles River Stock 15 Years Ago, You Would Have This Much Today
Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 2.07% on an annualized basis producing an average annual return of 15.79%. Currently, Charles River has a market capitalization of $14.32
Benzinga21 days agoCRL
5 Insightful Analyst Questions From Charles River Laboratories’s Q2 Earnings Call
Charles River Laboratories’ second quarter results were shaped by recovering biopharmaceutical demand and the impact of portfolio streamlining. Management highlighted that the rebound was most evident in the Discovery and Safety Assessment (DSA) segment, where net book-to-bill reached a four-year high and organic revenue growth turned positive for the first time since 2023. CEO Birgit Girshick pointed to an uptick in proposal activity and improved funding for small and midsize biotech clients as
Yahoo21 days agoCRL
Charles River Laboratories (CRL) Q2 2026 Earnings Call Transcript
Organic revenue returned to growth as biopharmaceutical demand strengthened.
Yahoo23 days agoCRL
CRAI Jumps 20% in 3 Months as Demand Broadens Across Key Practices
CRAI's 20% three-month gain is backed by broader demand, a stronger project pipeline and higher fiscal 2026 revenue guidance, but costs remain a drag.
Yahoo24 days agoCRL
International Markets and Charles River (CRL): A Deep Dive for Investors
Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Yahoo25 days agoCRL
TD Cowen Maintains Buy on Charles River, Raises Price Target to $300
TD Cowen analyst Charles Rhyee maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $235 to $300.
Benzinga25 days agoCRL
Morgan Stanley Maintains Overweight on Charles River, Raises Price Target to $300
Morgan Stanley analyst Ricky Goldwasser maintains Charles River (NYSE:CRL) with a Overweight and raises the price target from $260 to $300.
Benzinga28 days agoCRL
This SpaceX Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Wall Street analysts upgraded AVITA, Etsy, Unity, and raised target prices for these stocks. See what others think before buying Unity.
Benzinga28 days agoCRL
JP Morgan Upgrades Charles River Laboratories International (CRL)
Fintel29 days agoCRL